<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411199</url>
  </required_header>
  <id_info>
    <org_study_id>D-PLEX 312</org_study_id>
    <nct_id>NCT04411199</nct_id>
  </id_info>
  <brief_title>D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)</brief_title>
  <acronym>D-PLEX 312</acronym>
  <official_title>D-PLEX 312 - Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX In Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PolyPid Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PolyPid Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double&#xD;
      Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the&#xD;
      Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post&#xD;
      Abdominal Surgery Incisional Infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      D-PLEX is a new formulation of extended controlled release of Doxycycline in the applied area&#xD;
      for about 30 days. This study is aimed to assess the safety and efficacy of D-PLEX in&#xD;
      prevention of post abdominal surgery incisional infection.&#xD;
&#xD;
      The study population includes male and female, 18 years old and above at screening,&#xD;
      undergoing an elective colorectal surgery involving colon or rectal resection, with or&#xD;
      without a stoma formation, that includes at least 1 incision that is ≥ 7cm (target incision).&#xD;
&#xD;
      Eligible and willing subjects will be randomly allocated into 2 blinded study arms, either to&#xD;
      the investigational arm (D-PLEX + SoC) or to the control arm (SoC only) in a 1:1 ratio.&#xD;
      Subjects will be stratified by incisional length (7cm ≤10 cm, &gt;10 ≤20cm, &gt;20cm), type of&#xD;
      prophylactic SoC (IV antibiotic only, IV antibiotic with mechanical bowel preparation or IV&#xD;
      antibiotic with oral antibiotics combined with mechanical bowel preparation) and by region&#xD;
      (US versus Europe + Israel).&#xD;
&#xD;
      D-PLEX will be applied during the surgery at the final stage of incision closure. All&#xD;
      patients will be followed up for additional 5 visits over 2 months, for safety and incisional&#xD;
      wound assessment. This will include blood tests for hematology and chemistry as well as&#xD;
      physician's assessment of the incisional wound.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Males and females, &gt;18 years old, undergoing scheduled abdominal colon surgery involving resection and anastomosis or a stoma, who meet the inclusion criteria and none of the exclusion criteria and provide signed informed consent will be enrolled in the study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a double-blind clinical trial. The sponsor, the subjects, outcomes assessor and all staff involved in the collection and recording of the clinical and laboratory data, based on which the independent adjudication committee will perform their assessment, will be blind to treatment assignment. In addition, all aspects of data management and clean-up will be done in blinded datasets.&#xD;
The study site personnel, who perform the index surgery (Operation room staff), will be trained not to disclose the treatment arm to the blinded Investigator, to the subject, his/her family, to other health care providers not present during the surgery or to the study Sponsor representatives. Wound assessment throughout the study follow-up visits will be done by a blinded Investigator, that will not be involved in the surgery. An emergency card containing the Study Name, NIH number, Center Name/number, PI's name and contact details will be provided to the subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the anti-infective efficacy of D-PLEX over a period of 30 days post operation, by preventing surgical site infection (SSI), defined as superficial and deep infection, in the target incision(s), compared to the SoC treated control.</measure>
    <time_frame>By day 30 post surgery</time_frame>
    <description>Infection rate as measured by the proportion of subjects with at least one abdominal incisional infection event, as determined by a blinded and independent adjudication committee, within 30 days post abdominal surgery. [abdominal incisional infection is composed of Deep Incisional Surgical Site Infection (DSSI) and Superficial Incisional Surgical Site Infection (SSSI)].within 30 days post abdominal surgery and determined by a blinded and independent adjudication committee.&#xD;
All-cause mortality and re-interventions in the target incision within 30 days post index surgery will be analysed as treatment failure.&#xD;
Incisional infection event only, occurred within 30 days post abdominal surgery and determined by a blinded and independent adjudication committee.&#xD;
[abdominal incisional infection is defined as Deep Incisional Surgical Site Infection (DSSI) and/or Superficial Incisional Surgical Site Infection (SSSI)].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of D-PLEX in Prevention of Post Abdominal Surgery</measure>
    <time_frame>By day 60 post surgery</time_frame>
    <description>Safety parameters will be evaluated by adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of D-PLEX in Prevention of Post Abdominal Surgery Incisional</measure>
    <time_frame>By day 60 post surgery</time_frame>
    <description>Incisional wound healing will be assessed by a blinded Investigator, using a visual examination as well as Modified Vancouver Scar Scale wound assessment questionnaires. The questionnaire has a numeric scale from 0-4 in Vascularity, Pigmentation, Pliability and height</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Infection rate in patient undergoing abdominal colon surgery</measure>
    <time_frame>At study visits: day 1, day 5, day 14 and day 30 post surgery</time_frame>
    <description>Infection rate as measured by the proportion of subjects with at least one abdominal incisional infection event only, occurred within 30 days post abdominal surgery and determined by a blinded and independent adjudication committee.&#xD;
[abdominal incisional infection is defined as Deep Incisional Surgical Site Infection (DSSI) and/or Superficial Incisional Surgical Site Infection (SSSI)].</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Surgical Site Infection</condition>
  <condition>Colon Surgery</condition>
  <condition>Abdominal Surgery</condition>
  <condition>Post-Op Infection</condition>
  <arm_group>
    <arm_group_label>D-PLEX+SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The SoC for prophylactic antibiotic treatment is based on international guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-PLEX</intervention_name>
    <description>D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.</description>
    <arm_group_label>D-PLEX+SoC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care (SoC)</intervention_name>
    <description>prophylactic, pre-operation per institution guidelines</description>
    <arm_group_label>D-PLEX+SoC</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects undergoing a colorectal surgery involving resection, with or without a stoma&#xD;
             formation, that includes at least 1 incision that is ≥ 7cm (target incision).&#xD;
&#xD;
          2. Subjects are preoperative hemodynamically stable.&#xD;
&#xD;
          3. Male or non-pregnant female.&#xD;
&#xD;
          4. Female of child-bearing potential should have a negative pregnancy test (serum or&#xD;
             urine dipstick) prior to index procedure. Note: All female subjects of child-bearing&#xD;
             potential must agree to use a highly effective method of contraception consistently&#xD;
             and correctly for the duration of the study.&#xD;
&#xD;
          5. Subjects age 18 years old and above at screening.&#xD;
&#xD;
          6. Subjects who sign a written Informed Consent Form.&#xD;
&#xD;
          7. Subjects who are willing and able to participate and meet all study requirements.&#xD;
&#xD;
          8. Survival expectancy of at least 60 days post randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with any preoperative infection or who are receiving any antibiotic therapy&#xD;
             in the past 1 week prior to randomization, besides prophylaxis or antibiotic for the&#xD;
             treatment of the disease that consists the indication for surgery.&#xD;
&#xD;
          2. Subjects undergoing concomitant additional major procedures besides abdominal surgery.&#xD;
             Female sterilization surgery (i.e. salpingo-oophorectomy etc.), involvement of a small&#xD;
             bowel procedure or cholecystectomy may be allowed, pending an advanced consultation&#xD;
             and approval from the Sponsor.&#xD;
&#xD;
          3. Subject received anti-cancer treatment within the last 4 weeks of surgery, or&#xD;
             radiation for colorectal cancer to the abdomen area, prior to the planned abdominal&#xD;
             surgery.&#xD;
&#xD;
          4. Subjects that received oral or IV Doxycycline/Tetracycline family antibiotic during&#xD;
             the past 4 weeks prior to randomization.&#xD;
&#xD;
          5. Subjects with known allergy to Doxycycline and/or to the tetracycline family of drugs&#xD;
             or to the D-PLEX's excipients.&#xD;
&#xD;
          6. Subjects with known allergies to more than 3 substances (an allergy questionnaire will&#xD;
             be filled in during the screening process).&#xD;
&#xD;
          7. Subjects with history of severe allergic reaction to any substance, having required&#xD;
             treatment with intravenous steroids/intramuscular epinephrine, or in the opinion of&#xD;
             the Investigator the subject is at high risk of developing severe allergic reactions.&#xD;
&#xD;
          8. Subjects with End Stage Renal Disease (ESRD/CKD stage 5).&#xD;
&#xD;
          9. Subjects with chronic urticaria.&#xD;
&#xD;
         10. Subjects diagnosed with CVA within the past 6 months prior to randomization.&#xD;
&#xD;
         11. Subjects that undergone any abdominal surgery and current planned surgery involves&#xD;
             re-opening the scar of a prior abdominal surgery performed within the last 5 years.&#xD;
&#xD;
         12. Any subject with active malignancy or with malignancy that has not been in complete&#xD;
             remission for at least 3 years. Excluding:&#xD;
&#xD;
               -  Subjects with potentially resectable non-metastatic cancer which consists of the&#xD;
                  indication for the surgery.&#xD;
&#xD;
               -  Subjects who have had carcinoma in situ (or other cancer &quot;in situ = Stage 0&quot;),&#xD;
                  squamous cell carcinoma of the skin and basal cell carcinoma of the skin.&#xD;
&#xD;
               -  Subjects with any additional non-violent cancer (slowly growing, localized or&#xD;
                  chronic cancers), that does not require treatment 4 weeks prior to the surgery,&#xD;
                  and throughout the entire study duration.&#xD;
&#xD;
         13. Subjects with other concurrent severe and/or uncontrolled medical condition that could&#xD;
             compromise participation in the study.&#xD;
&#xD;
         14. Psychiatric or any other disorder that compromises ability to provide Informed Consent&#xD;
             Form for participation in this study.&#xD;
&#xD;
         15. Chronic alcoholic or drug abuse subjects.&#xD;
&#xD;
         16. Pregnant or breast-feeding women or women of child-bearing age who refuse or&#xD;
             prohibited of using an effective contraceptive method of birth control throughout&#xD;
             study participation, including safety follow-up period.&#xD;
&#xD;
         17. Subjects that received any investigational drug within 30 days or 5 half-lives of&#xD;
             randomization to the study (whichever is longer).&#xD;
&#xD;
         18. Subjects participating in any other interventional studies.&#xD;
&#xD;
         19. In the opinion of Investigator, subject is not eligible to participate in the study&#xD;
             and/or to comply with protocol requirements (e.g. due to a cognitive or medical&#xD;
             condition).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilana Sufaro, CPM</last_name>
    <phone>+972 74-7195700</phone>
    <email>ilana.s@polypid.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lital Weinfeld Bergman, COM</last_name>
    <phone>+972 74-7195700</phone>
    <email>lital.wb@polypid.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radhika Smith, Dr.</last_name>
      <phone>314-362-2646</phone>
      <email>radhikasmith@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Fichera, Dr.</last_name>
      <phone>469-800-7180</phone>
      <email>Alessandro.Fichera@BSWHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HD Research LLC / Memorial Hermann Southeast Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Rafiq, Dr.</last_name>
      <phone>713-480-3028</phone>
      <email>hminkowitz@lotuscr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uzsoki utcai Kórház, Sebészeti Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristof Dede, Dr.</last_name>
      <phone>36 1 467 3700</phone>
      <phone_ext>1634</phone_ext>
      <email>dede.kristof@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bács-Kiskun Megyei Kórház</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>László Sikorszki, Prof.</last_name>
      <phone>36 76 516 700</phone>
      <phone_ext>5154</phone_ext>
      <email>sikorszkil@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flór Ferenc Kórház</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt T. Csapo, Dr.</last_name>
      <phone>(36) 28 507 600</phone>
      <email>csapo.zsolt@florhosp.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lajos B. Toth, Dr.</last_name>
      <phone>(36) 42 599-700</phone>
      <phone_ext>1210</phone_ext>
      <email>dr.toth.lajos.barna@szszbmk.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Általános Orvostudományi Kar Szent-Györgyi Albert Orvostudományi Központ</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>György Lazar, Prof.</last_name>
      <phone>(36) 62 545 701</phone>
      <email>gylazar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent Borbála Kórház</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balázs Banky, Prof.</last_name>
      <phone>(36) 34 515 488</phone>
      <phone_ext>407</phone_ext>
      <email>bankybalazs@tatabanyakorhaz.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Czeiger, Dr.</last_name>
      <phone>972-54-4761408</phone>
      <email>DudyC@CLALIT.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Orian Sinhon</last_name>
      <phone>972-8-6292822</phone>
      <email>oriansi@clalit.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gideon Sroka, Dr.</last_name>
      <phone>04-8359137</phone>
      <email>gideon.sroka@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wissam Khouri, Dr.</last_name>
      <phone>04-8250490</phone>
      <email>wisamk@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek MC</name>
      <address>
        <city>Jerusalem</city>
        <zip>9372212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petachia Reissman, Prof.</last_name>
      <phone>02-6666310</phone>
      <email>reissman@szmc.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCK im. Prof. K. Gibinskiego, Oddziat Chirurgii Przewodu Pokarmowego</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slawomir Mrowiec, Dr.</last_name>
      <phone>+48 32 7894251</phone>
      <email>mrowasm@poczta.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital im. M. Curie-Skłodowskiej w Ostrowie Mazowieckim</name>
      <address>
        <city>Wołomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemyslaw Ciesielski, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny we Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Śmigielski, Prof.</last_name>
      <phone>+48 60 1365926</phone>
      <email>smiglo@mp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med.-Gastr Łódź</name>
      <address>
        <city>Łódź</city>
        <zip>91-032</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkadiusz Mamos, Dr.</last_name>
      <phone>+48 42 2582223</phone>
      <email>arkadiusz.mamos@medgastr.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Kragujevac, General and Thoracic Surgery Clinic</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radisav Bogojevic, Dr.</last_name>
      <phone>(00-381)-64-132-8479</phone>
      <email>drrasabogojevic@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis, Clinic for Digestive Surgery</name>
      <address>
        <city>Nis</city>
        <zip>18108</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milica Nestorovic, Dr.</last_name>
      <phone>(00-381)-63-590-900</phone>
      <email>milica20@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology of Vojvodina, Clinic of Operative Oncology</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mladjan Protic, Dr.</last_name>
      <phone>(00-381)-64-125-3308</phone>
      <email>mlprotic@gmail.com; protic.mladjan@onk.ns.ac.rs</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical site infection</keyword>
  <keyword>Abdominal surgery</keyword>
  <keyword>Colon and small bowl surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

